RIGL: Rigel Pharmaceuticals Inc. (New) Company Profile & Statistics

About

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

Info & Links

CEO

Raul R. Rodriguez

Headquarters

611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

164

Rigel Pharmaceuticals Inc. (New) Statistics

Valuation Measures

Market Capitalization²

301.41M

Enterprise Value

304.35M

Enterprise Value/EBITDA(ttm)

11.84

Price to Earnings Ratio(ttm)

148.79

Price to Sales(ttm)

2.33

Price to Book(mrq)

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

90.24%

Operating Margin(ttm)

2.46%

Profit Margin(ttm)

4.16%

Return on Equity(ttm)

-14.80%

Return on Invested Capital(ttm)

-12.01%

Return on Assets(ttm)

3.03%

Income Statement

Revenue(ttm)

179.28M

Revenue Per Share(ttm)

10.04

Gross Profit(ttm)

160.63M

EBITDA(ttm)³

25.71M

Net Income Available to Common(ttm)

17.48M

Diluted EPS(ttm)

0.14

Share Statistics

Beta (5Y Monthly)

1.34

52-Week Change

51.82%

S&P 500 52-Week Change

5.42%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

17.86M

Dividend Yield

0.00%

Float⁴

16.02M

% Held by Insiders

9.04%

% Held by Institutions

66.23%

Balance Sheet

Total Cash(mrq)

77.32M

Total Cash Per Share(mrq)

4.33

Total Debt(mrq)

59.68M

Total Debt/Equity(mrq)

1815.09%

Current Ratio(mrq)

2.13%

Quick Ratio(mrq)

1.87%

Book Value Per Share(mrq)

0.19

Cash Flow

Operating Cash Flow Per Share(ytd)

1.78

Free Cash Flow(ytd)

31.53M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

RIGL

Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals Inc. (New) Profile